image credit: Adobe Stock

Vanda Pharmaceuticals, OliPass Enter ASO R&D Alliance

September 30, 2022

Vanda Pharmaceuticals Inc. and OliPass Corp. have entered into a research and development collaboration to jointly develop a set of antisense oligonucleotide (ASO) molecules based on OliPass’ modified peptide nucleic acids. The partnership leverages the respective strengths of Vanda and OliPass to support the development of ASO-based precision medicine therapeutics and potentially create compelling value opportunities for both companies.

The collaboration will focus on editing and modifying gene expression using ASOs in disease states where the expression of genes is either altered or the sequence of the expressed genes can be altered for therapeutic benefit. Olipass’ Peptide Nucleic Acids (OPNA) technology provides the delivery platform to enable these gene expression modifications.

Read More on Contract Pharma